Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study

por Shen, Xia-Bo, Li, Guang-Liang, Zheng, Ya-Bing, Chen, Zhan-Hong, Cao, Wen-Ming, Wang, Xiao-Jia, Shao, Xi-Ying
Publicado 2021

Efficacy of fulvestrant 500 mg in Chinese postmenopausal women with advanced/recurrent breast cancer and factors associated with prolonged time-to-treatment failure: A retrospectiv...

por Huang, Jian, Huang, Ping, Shao, Xi-ying, Sun, Yan, Lei, Lei, Lou, Cai-jin, Ye, Wei-wu, Chen, Jun-qing, Cao, Wen-ming, Huang, Yuan, Zheng, Ya-bing, Wang, Xiao-jia, Chen, Zhan-hong
Publicado 2020

Cardiac Safety in Breast Cancer Patients Receiving Pegylated Liposome Doxorubicin Sequential Anti-HER2 Monoclonal Antibody Therapy

por Huang, Ping, Huang, Jia-huan, Zheng, Ya-bing, Cao, Wen-ming, Shao, Xi-ying, Chen, Jun-qing, Huang, Yuan, Li, Guang-liang, Sharma, K, Zhou, Huan-huan, Wang, Xiao-jia, Jin, Hong-chuan, Chen, Zhan-hong
Publicado 2022